Brind.

Viking Therapeutics is developing a drug for obesity, while analysts project global drug market growth to $150B by 2035.

2 reports, 2 independent Updated Jun 10
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Viking Therapeutics is developing a drug for obesity, while analysts project global drug market growth to $150B by 2035.

Who's involved

What this event is mainly about
Viking TherapeuticsMorgan Stanley

How it developed

Newest first. Tap a step to see who reported it.
  1. Morgan Stanley set an $83 price target on Viking Therapeutics, which is developing an obesity drug.1 source
  2. Morgan Stanley set a high price target for Viking Therapeutics, noting the need for FDA approval.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped